From September 25 to 27, 2021, the Sixth China BioMed Innovation and Investment Conference (hereinafter referred to as the "conference") supported by ZVCA was grandly held in Suzhou Industrial Park. The conference would promote the combination of domestic and foreign social capital and pharmaceutical innovation, improve the innovation ability of China's pharmaceutical industry, take promoting the global pharmaceutical innovation and development and the in-depth cooperation between global capital and pharmaceutical innovation under the new era and new pattern as the theme, focus on the industrial policies leading the innovation and development, global pharmaceutical R & D trends and investment and financing trends, and serve industry leaders, experts scholars, domestic and foreign pharmaceutical innovation enterprises and investors to build a professional and multi-dimensional platform for dialogue, communication and cooperation .
Kevin LIN, Vice President of ZVCA,Managing Partner of DNV Capital Limited
HE Fengzhi, Vice President of ZVCA,General Manager of Beikang Healthcare
LI Anmin, Vice President of ZVCA, President of Eagle Holdings Co., Ltd
Dr. Li Anmin presided over the forum of Financing M & A to discuss the new trend of global pharmaceutical investment and financing with industry guests, share the development history of Chinese Biomedical enterprises, comment on the project’s highlights and investment ideas of the speakers, interpret relevant medical regulatory policies, and point out the difficulties and opportunities of pharmaceutical enterprises under the background of economic adjustment and transformation.